Should Buscopan (hyoscine butylbromide) be given for pain relief in biliary colic caused by gallstones?

Buscopan for Biliary Stone Pain

Buscopan (hyoscine butylbromide) should NOT be used as first-line treatment for biliary colic pain relief. NSAIDs, particularly diclofenac, are superior for pain control and may prevent progression to acute cholecystitis, while Buscopan lacks evidence for efficacy in this specific indication.

Evidence-Based Reasoning

Why NSAIDs Are Preferred

The available evidence strongly favors NSAIDs over antispasmodics for biliary colic:

• Diclofenac provides significantly faster and more complete pain relief than hyoscine butylbromide. In a head-to-head trial, 91.7% of patients receiving diclofenac 75mg IM achieved complete pain relief at 4 hours versus only 69.4% with hyoscine 20mg IM 1.

• NSAIDs may prevent disease progression: Most remarkably, only 16.7% of diclofenac-treated patients progressed to acute cholecystitis compared to 52.8% in the hyoscine group 1. This represents a critical difference in morbidity outcomes.

• A Cochrane systematic review confirmed NSAIDs significantly reduce the proportion of patients without complete pain relief compared to placebo (RR 0.27,95% CI 0.19-0.40) 2.

The Problem with Buscopan

Buscopan actually inhibits gallbladder emptying, which is counterproductive in biliary colic:

• Hyoscine butylbromide significantly inhibits cholecystokinin-induced gallbladder contraction in a dose-dependent manner 3. This anticholinergic effect relaxes smooth muscle but prevents the physiologic gallbladder emptying that could help resolve the obstruction.

• The drug label provided 4 describes buspirone (an anxiolytic), NOT Buscopan/hyoscine butylbromide—this appears to be a documentation error. However, the research evidence on actual hyoscine butylbromide shows it lacks specific efficacy for biliary colic pain.

• Recent evidence shows hyoscine-N-butylbromide provides no significant pain reduction versus placebo for abdominal cramping pain in gastroenteritis 5, raising questions about its analgesic efficacy for visceral pain.

Clinical Application Algorithm

For acute biliary colic pain:

1. First-line: Diclofenac 75mg IM or ketorolac 30mg IV/IM

   • Provides rapid pain relief (within 30 minutes)
   • May prevent progression to cholecystitis
   • Contraindications: active GI bleeding, severe renal impairment, NSAID allergy

2. Second-line (if NSAIDs contraindicated): Opioids (e.g., pethidine/meperidine)

   • Evidence shows similar pain control to NSAIDs 2
   • Does not prevent disease progression

3. Avoid: Buscopan/hyoscine butylbromide as primary analgesic

   • May be used adjunctively during intraoperative cholangiography to facilitate stone passage 6, 7, but this is a different clinical context
   • Not supported for acute pain management

Important Caveats

• The 1993 American College of Physicians guidelines [8-8] focus on long-term management (cholecystectomy vs. expectant management) but do not address acute pain management pharmacotherapy.

• While Buscopan is used in some centers during intraoperative cholangiography to relax the sphincter of Oddi and facilitate stone passage (with 55% success rate) 6, this specialized application differs from treating acute biliary colic pain in the emergency setting.

• Definitive treatment remains cholecystectomy for symptomatic gallstones to prevent recurrent pain and complications 8.